Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.

El Amin Ali AM, Osman HM, Zaki AM, Shaker O, Elsayed AM, Abdelwahed MY, Mohammed RA

Iranian journal of basic medical sciences1 Dec 2022Cited by 5 (Europe PMC)

PMID36544522PMCIDPMC9742563DOI10.22038/ijbms.2022.65061.14494PepBankPUB-36544522

Summary

ObjectivesThe prevalence of chronic kidney disease in diabetics is progressively increasing with an increased risk of fatal complications.Materials and methodsSixty male albino rats were used in the study, and type 2 diabetes mellitus were induced. Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6). At the end of the experiment, the weight of rats and systolic blood pressure were estimated. After overnight fasting, the serum levels of blood glucose, lipid profile, and kidney function were measured. After scarification, gene expression of eNOS and NFKB in kidney tissue were estimated and kidney tissues were examined for histopathology.ResultsDiabetic rats showed a significant increase in body weight, blood pressure, serum blood glucose, lipid profile, and impaired kidney function. Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function. These changes are associated with a significant increase in anti-oxidative markers, and decreased inflammatory and fibrotic markers, especially with the addition of cilostazol.ConclusionMetformin and dulaglutide have been shown to ameliorate kidney damage in diabetics by stimulating the anti-oxidant defense system, normalizing kidney functional parameters, and improving histopathological changes. The addition of cilostazol to metformin or dulaglutide increased some of their anti-oxidants and anti-inflammatory properties.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic male albino rats, dulaglutide was associated with lower blood pressure than diabetic control treatment.
In plain wordsIn rats with diabetes, dulaglutide was linked to lower blood pressure than diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBlood pressure
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
Show in the study text Report a problemFND-3654452201
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic male albino rats, dulaglutide was associated with lower blood glucose than diabetic control treatment.
In plain wordsIn rats with diabetes, dulaglutide was linked to lower blood sugar than diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBlood glucose
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
Show in the study text Report a problemFND-3654452202
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic male albino rats, dulaglutide was associated with a decreased serum lipid profile versus diabetic control treatment.
In plain wordsIn rats with diabetes, dulaglutide was linked to a lower blood lipid profile than diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSerum lipid profile
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
Show in the study text Report a problemFND-3654452203
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic male albino rats, dulaglutide was associated with improved kidney function versus diabetic control treatment.
In plain wordsIn rats with diabetes, dulaglutide was linked to better kidney function than diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableKidney function
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
Show in the study text Report a problemFND-3654452204

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

05AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism
In diabetic rats, metformin and dulaglutide regimens were associated with increased antioxidative markers, especially with added cilostazol.
In plain wordsIn rats, regimens involving metformin or dulaglutide increased antioxidant markers, especially with cilostazol, compared with diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAntioxidative markers across regimens
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
These changes are associated with a significant increase in anti-oxidative markers, and decreased inflammatory and fibrotic markers, especially with the addition of cilostazol.
3 context sentences(design, population, supporting numbers)
Summary · context
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3654452205
06AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism
In diabetic rats, metformin and dulaglutide regimens were associated with decreased inflammatory markers, especially with added cilostazol.
In plain wordsIn rats, regimens involving metformin or dulaglutide reduced inflammatory markers, especially with cilostazol, compared with diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseInflammatory markers across regimens
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
These changes are associated with a significant increase in anti-oxidative markers, and decreased inflammatory and fibrotic markers, especially with the addition of cilostazol.
3 context sentences(design, population, supporting numbers)
Summary · context
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3654452206
07AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism
In diabetic rats, metformin and dulaglutide regimens were associated with decreased fibrotic markers, especially with added cilostazol.
In plain wordsIn rats, regimens involving metformin or dulaglutide reduced fibrosis markers, especially with cilostazol, compared with diabetic control treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFibrotic markers across regimens
Study
ratn: not reported in source
Experimentally induced type 2 diabetes in male albino rats
Comparator
Control diabetic group
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
These changes are associated with a significant increase in anti-oxidative markers, and decreased inflammatory and fibrotic markers, especially with the addition of cilostazol.
3 context sentences(design, population, supporting numbers)
Summary · context
Metformin and dulaglutide are associated with a significant decrease in blood pressure, blood glucose level, serum lipid profile, and improved kidney function.
Summary · context
Sixty male albino rats were used in the study, and type 2 diabetes mellitus were induced.
Summary · context
Diabetic rats were divided randomly into 5 groups, the control diabetic group and 4 treated groups were treated with metformin (group3), dulaglutide (group 4), metformin & cilostazol (group 5), and the last group was treated with dulaglutide & cilostazol (group 6).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3654452207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.